Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
Incyte completed its acquisition of Vega Therapeutics from Star Therapeutics for $1.25 billion upfront to expand its hematology portfolio. The deal adds VGA039, a Phase 3 monoclonal antibody for von Willebrand disease which holds FDA Breakthrough Therapy and orphan drug designations.
Key figures
- Drug Name
- VGA039
- Deal Value Usd
- 1250000000
- Phase Of Trial
- Phase 3
- Trial id
- NCT07115004
- Milestone payments usd
- 750000000
- Vwd patients diagnosed us
- 135000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.